Based on the provided paper content, here are the answers to the questions:

"""
Question: 1101

Evidence: This was a retrospective, non-interventional study, and patient information was anonymized and de-identified prior to analysis. All data supporting our findings is contained within the manuscript.

Rationale: The paper explicitly states that it is a retrospective, non-interventional study and that all supporting data is contained within the manuscript, indicating that the data presented is from the authors' own research and analysis, not previously published elsewhere.

Answer: Yes
"""

"""
Question: 1102

Evidence: We have performed a pilot, observational, retrospective, non interventional study, including 7 patients infected by HIV-1. Integrase was amplified using a nested-PCR. For Sanger sequencing, we used a bidirectional sequencing protocol.

Rationale: The paper describes sequencing the Integrase region of HIV-1 from patient samples using PCR and Sanger sequencing, which inherently involves reporting HIV sequences.

Answer: Yes
"""

"""
Question: 1103

Evidence: The paper content does not mention any in vitro passage experiments.

Rationale: After a thorough review of the entire paper content, no references to in vitro passage experiments were found. The study is focused on clinical patient samples and proviral DNA analysis.

Answer: No
"""

"""
Question: 1104

Evidence: The paper content does not report any in vitro antiretroviral susceptibility data.

Rationale: The paper focuses on genotypic resistance testing through sequencing of the Integrase region, but does not mention any phenotypic susceptibility testing or in vitro drug susceptibility assays.

Answer: No
"""

"""
Question: 2101

Evidence: The paper content does not mention GenBank accession numbers.

Rationale: After reviewing all sections of the paper including methods, results, and data availability statements, no GenBank accession numbers are referenced for any sequenced HIV isolates.

Answer: No
"""

"""
Question: 2102

Evidence: The paper content does not mention GenBank accession numbers.

Rationale: Since no GenBank accession numbers are reported at all in the paper, there are certainly none reported for HIV isolates other than laboratory isolates.

Answer: No
"""

"""
Question: 2103

Evidence: The paper content does not mention GenBank accession numbers.

Rationale: No GenBank accession numbers are referenced anywhere in the paper content.

Answer: NA
"""

"""
Question: 2202

Evidence: Table 2 shows the correlation on resistance mutations (Sanger sequencing) detected at RAL failure in plasma and on proviral DNA. Patients are indicated with the numbers 1 to 7; F relates to the time point of therapeutic failure (plasma RNA), A to the proviral DNA studies after virological suppression.

Rationale: Table 2 provides detailed lists of mutations (major resistance mutations, accessory mutations, and polymorphism mutations) for each of the 7 individual patients at both failure and proviral DNA timepoints.

Answer: Yes
"""

"""
Question: 2301

Evidence: All the patients were infected by HIV-1 B subtypes.

Rationale: The paper explicitly states that all patients were infected by HIV-1, specifically B subtypes.

Answer: HIV-1
"""

"""
Question: 2302

Evidence: All the patients were infected by HIV-1 B subtypes.

Rationale: The results section clearly states that all patients were infected by HIV-1 B subtypes.

Answer: B subtypes
"""

"""
Question: 2303

Evidence: A genotypic viral Integrase region study was available for each patient at the moment of RAL failure. Integrase was amplified using a nested-PCR.

Rationale: The methods section describes that the Integrase region was specifically targeted for amplification and sequencing in this study.

Answer: Integrase
"""

"""
Question: 2304

Evidence: The paper content does not mention sequencing of the pol gene.

Rationale: While the Integrase gene is part of the pol region, the paper specifically focuses on sequencing only the Integrase region, not the broader pol gene that would include protease and reverse transcriptase.

Answer: No
"""

"""
Question: 2401

Evidence: All the patients were infected by HIV-1 B subtypes, with a mean age of 55 (range 43 to 56), originating from Spain.

Rationale: The results section explicitly states that all patients originated from Spain.

Answer: Spain
"""

"""
Question: 2402

Evidence: Table 1 shows dates of failure ranging from 13/8/2009 to 26/10/2012. The median time (IQR) between previous failure to RAL and the study on proviral DNA was 48 (29-53) months.

Rationale: Table 1 provides specific failure dates for each patient, and the text indicates the time interval between failure and proviral DNA testing, allowing inference of sample collection years.

Answer: 2009-2012
"""

"""
Question: 2502

Evidence: For Sanger sequencing, we used a bidirectional sequencing protocol. Sanger sequencing correctly identified all the secondary mutations.

Rationale: The methods section explicitly describes using Sanger sequencing, and the results confirm its use and performance.

Answer: Yes
"""

"""
Question: 2503

Evidence: Ultra Deep Sequencing (UDS) was done using an HIV-1 UDS prototype (Roche diagnostics) and the 454 GS Junior (Roche 454 Life Sciences Branford, CT).

Rationale: The methods section describes using Ultra Deep Sequencing (UDS) with 454 GS Junior technology, which is an NGS (Next Generation Sequencing) platform.

Answer: Yes
"""

"""
Question: 2504

Evidence: The paper content does not mention cloning of samples prior to sequencing.

Rationale: After reviewing the methods section, no mention is made of cloning procedures. The sequencing methods described involve direct PCR amplification and sequencing.

Answer: No
"""

"""
Question: 2505

Evidence: The paper content does not mention single genome sequencing.

Rationale: The sequencing methods described involve population sequencing (Sanger) and ultra deep sequencing, but single genome sequencing is not mentioned.

Answer: No
"""

"""
Question: 2506

Evidence: The paper content does not mention molecular cloning.

Rationale: The methods describe PCR amplification and sequencing procedures but do not mention any molecular cloning steps.

Answer: No
"""

"""
Question: 2601

Evidence: A genotypic viral Integrase region study was available for each patient at the moment of RAL failure.

Rationale: The paper states that genotypic studies were available at the time of RAL failure, which typically involves plasma virus sequencing when patients have detectable viral load.

Answer: Yes
"""

"""
Question: 2602

Evidence: Integrase resistance mutations in proviral DNA were studied. Peripheral Blood Mononuclear Cells (PBMC) were separated by Ficoll gradient centrifugation.

Rationale: The study explicitly describes sequencing from proviral DNA obtained from PBMCs.

Answer: Yes
"""

"""
Question: 2603

Evidence: We have performed a pilot, observational, retrospective, non interventional study, including 7 patients infected by HIV-1.

Rationale: The study included 7 patients, and genotypic testing was available for each at the time of RAL failure, indicating plasma sequencing was performed on all 7 patients.

Answer: 7
"""

"""
Question: 2604

Evidence: We have performed a pilot, observational, retrospective, non interventional study, including 7 patients infected by HIV-1. Integrase resistance mutations in proviral DNA were studied.

Rationale: The study included 7 patients and proviral DNA sequencing was performed on all of them, as evidenced by Table 2 which shows proviral DNA results for all 7 patients.

Answer: 7
"""

"""
Question: 2605

Evidence: A genotypic viral Integrase region study was available for each patient at the moment of RAL failure.

Rationale: Sequencing at the time of RAL failure would have been performed when patients had active HIV replication and detectable viral load.

Answer: Yes
"""

"""
Question: 2606

Evidence: Integrase resistance mutations in proviral DNA were studied.

Rationale: The study explicitly focused on sequencing from proviral DNA obtained from PBMCs, which represents the proviral DNA reservoir.

Answer: Yes
"""

"""
Question: 2701

Evidence: All the patients were infected by HIV-1 B subtypes, with a mean age of 55 (range 43 to 56).

Rationale: The age range of patients (43-56 years) indicates they were all adults, with no mention of infants or children in the study.

Answer: No
"""

"""
Question: 2702

Evidence: We have performed a pilot, observational, retrospective, non interventional study.

Rationale: The paper describes the study as observational and non-interventional, which typically excludes clinical trials.

Answer: No
"""

"""
Question: 2703

Evidence: We have performed a pilot, observational, retrospective, non interventional study.

Rationale: The study is explicitly described as observational and non-interventional, not as a clinical trial.

Answer: No
"""

"""
Question: 3101

Evidence: We have performed a pilot, observational, retrospective, non interventional study, including 7 patients infected by HIV-1.

Rationale: The paper clearly states that 7 patients were included in the study and underwent HIV sequencing.

Answer: 7
"""

"""
Question: 3102

Evidence: We have performed a pilot, observational, retrospective, non interventional study, including 7 patients infected by HIV-1.

Rationale: The study included 7 patients and all underwent both plasma sequencing at failure and proviral DNA sequencing later.

Answer: Yes
"""

"""
Question: 4101

Evidence: All with a history of previous failure to a RAL containing regimen.

Rationale: All patients in the study had experienced treatment failure with RAL-containing regimens, indicating they were ART-experienced, not ART-naive.

Answer: No
"""

"""
Question: 4102

Evidence: All with a history of previous failure to a RAL containing regimen.

Rationale: The paper explicitly states that all patients had previous failure to a RAL-containing regimen, indicating they were ART-experienced.

Answer: Yes
"""

"""
Question: 4103

Evidence: All with a history of previous failure to a RAL containing regimen.

Rationale: Since all patients had previous treatment failure, there were no ART-naive individuals in the study.

Answer: No
"""

"""
Question: 4104

Evidence: All with a history of previous failure to a RAL containing regimen.

Rationale: All patients had experienced treatment failure, so there were no ART-naive individuals.

Answer: 0
"""

"""
Question: 4105

Evidence: The paper content does not provide complete ART history information for all individuals.

Rationale: While the paper mentions prior RAL failure, it does not provide comprehensive ART history details for all patients beyond their experience with integrase inhibitors.

Answer: No
"""

"""
Question: 4201

Evidence: The paper content does not discuss transmitted HIV drug resistance.

Rationale: The study focuses on acquired resistance in treatment-experienced patients, not transmitted drug resistance.

Answer: No
"""

"""
Question: 4202

Evidence: The paper content does not discuss pretreatment HIV drug resistance.

Rationale: The study examines resistance that emerged during treatment failure, not pretreatment resistance.

Answer: No
"""

"""
Question: 4301

Evidence: All with a history of previous failure to a RAL containing regimen.

Rationale: The paper specifically mentions that all patients had failed RAL-containing regimens, indicating they received integrase inhibitors.

Answer: Integrase inhibitors
"""

"""
Question: 4302

Evidence: All with a history of previous failure to a RAL containing regimen.

Rationale: The study explicitly focuses on patients who had received and failed RAL (raltegravir), which is an integrase inhibitor.

Answer: Yes
"""

"""
Question: 4303

Evidence: The paper content does not specify which other drug classes patients received.

Rationale: While patients likely received other drug classes in their salvage regimens, the paper does not explicitly mention protease inhibitors or other specific drug classes beyond integrase inhibitors.

Answer: NA
"""

"""
Question: 4304

Evidence: The paper content does not specify whether all patients received the same ART regimen.

Rationale: The paper mentions that all patients failed RAL-containing regimens but does not specify if the accompanying drugs were identical for all patients.

Answer: NA
"""

"""
Question: 4305

Evidence: All with a history of previous failure to a RAL containing regimen.

Rationale: All patients had previously failed RAL treatment, so they were not INSTI-naive.

Answer: No
"""

"""
Question: 4403

Evidence: The paper content does not provide specific information about the number of ART regimens each patient received.

Rationale: While the paper mentions prior RAL failure and subsequent salvage therapy, it does not specify how many ART regimens each patient received beyond this.

Answer: NA
"""

"""
Question: 4404

Evidence: The paper content does not provide specific information about the number of ART regimens each patient received.

Rationale: The paper does not contain details about the exact number of ART regimens for each patient.

Answer: NA
"""

"""
Question: 4405

Evidence: The paper content does not provide specific information about the number of ART regimens each patient received.

Rationale: Without information on the number of ART regimens per patient, it cannot be determined if all received the same number.

Answer: NA
"""

"""
Question: 4406

Evidence: All with a history of previous failure to a RAL containing regimen, that were successfully salvaged.

Rationale: Patients had at minimum a failing RAL regimen plus a successful salvage regimen, meaning they received at least two different ART regimens.

Answer: No
"""

"""
Question: 4501

Evidence: The paper content does not mention dolutegravir treatment for the study patients.

Rationale: While dolutegravir is discussed in the background and conclusions as a potential simplification option, the paper does not indicate that any patients actually received dolutegravir during the study period.

Answer: 0
"""

"""
Question: 4502

Evidence: The paper content does not mention darunavir treatment.

Rationale: Darunavir is not mentioned anywhere in the paper content.

Answer: 0
"""

"""
Question: 5101

Evidence: At Raltegravir failure, N155H was detected in four patients, and other secondary mutations were detected in five patients (71.4 %).

Rationale: The results show that 4 patients had major resistance mutations and 5 had secondary mutations, indicating multiple patients had drug resistance mutations.

Answer: 5
"""

"""
Question: 5102

Evidence: At Raltegravir failure, N155H was detected in four patients, and other secondary mutations were detected in five patients (71.4 %).

Rationale: Since RAL is an INSTI and the mutations detected are in the Integrase gene, these are INSTI-resistance mutations.

Answer: 5
"""

"""
Question: 5103

Evidence: The paper content does not mention TDF (tenofovir) or TDF-resistance mutations.

Rationale: The study focuses exclusively on Integrase inhibitor resistance and does not discuss nucleoside reverse transcriptase inhibitors like TDF.

Answer: 0
"""

"""
Question: 5104

Evidence: At Raltegravir failure, N155H was detected in four patients. In proviral DNA, N155H was detected by population sequencing in three patients (42.8 %), and UDS demonstrated a 9.77 % relative abundance of N155H in the remaining patient.

Rationale: The primary INSTI-resistance mutation reported is N155H, with secondary mutations including L74I, G163GR, T97A, and V151I as shown in Table 2.

Answer: N155H, L74I, G163GR, T97A, V151I
"""

"""
Question: 6101

Evidence: The paper content does not mention phenotypic susceptibility testing.

Rationale: The study exclusively uses genotypic methods (sequencing) and does not describe any phenotypic susceptibility testing.

Answer: NA
"""

"""
Question: 6102

Evidence: The paper content does not mention IC values like IC50 or IC90.

Rationale: No IC values are reported as the study focuses on genotypic resistance testing rather than phenotypic susceptibility.

Answer: No
"""

"""
Question: 6103

Evidence: The paper content does not mention IC50 fold change values.

Rationale: No fold change values are reported as phenotypic testing was not performed.

Answer: No
"""

"""
Question: 6104

Evidence: The paper content does not mention phenotypic susceptibility assays.

Rationale: The methods describe genotypic sequencing techniques but no phenotypic susceptibility assays.

Answer: NA
"""

"""
Question: 6105

Evidence: The paper content does not mention replication capacity.

Rationale: No data on replication capacity is presented in the paper.

Answer: No
"""

"""
Question: 6106

Evidence: The paper content does not mention phenotypic drug testing.

Rationale: Since phenotypic susceptibility testing was not performed, no drugs were tested using phenotypic assays.

Answer: NA
"""

"""
Question: 7101

Evidence: The paper content does not mention site-directed mutations.

Rationale: The study examines clinical isolates from patients, not laboratory-constructed site-directed mutants.

Answer: No
"""

"""
Question: 7102

Evidence: The paper content does not mention in vitro passage experiments.

Rationale: The study uses clinical samples from patients and does not describe any in vitro passage experiments.

Answer: No
"""